NIH Opposes Editing Human Embryos

Following the publication of a study in which scientists used CRISPR to edit nonviable human embryos, the National Institutes of Health states it will not fund such research.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, RWJMS IVF PROGRAMWhile the National Institutes of Health (NIH) supports the development of gene-editing technologies to produce knockout mouse models, develop new antimicrobials, and create HIV-resistant human immune cells, among other applications, the agency will not fund research seeking to edit human embryos, according to a statement released this week (April 29) from Director Francis Collins.

“The concept of altering the human germline in embryos for clinical purposes has been debated over many years from many different perspectives, and has been viewed almost universally as a line that should not be crossed,” Collins wrote. “Advances in technology have given us an elegant new way of carrying out genome editing, but the strong arguments against engaging in this activity remain.”

The statement was prompted by the publication of research in which scientists in China used the CRISPR-Cas9 system to edit nonviable human embryos, spurring much debate about the ethics of such manipulations. Many researchers believe that the technology is too immature to apply to human embryos. But not everyone agrees that the case is cut-and-dried.

“I am not in favor of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo